Despite FAERS limitations (underreporting bias, confounding factors), these findings advocate for tailored monitoring protocolsgradual dose titration, renal/thyroid surveillance in high-risk groups, and long-term vigilance for rare AEs
Toxic overload does not explain every case of depression, but oxidative stress, inflammation, mitochondrial dysfunction, medication sensitivity and impaired methylation may contribute to depressive symptoms in selected patients
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
doi: 10.1186/s40001-022-00691-2 71 HuH
In the following sections, we expand on the molecular, genetic, pharmacological, and phenomenological evidence that link CaMKK2 to bipolar disorder
The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota